The objective of this non-interventional, observational study is to assess the effectiveness and patient reported outcome of adalimumab in patients with moderate to severe psoriasis in real world clinical practice in China.

Inclusion Criteria:

• Participant who is in compliance with eligibility for adalimumab based on the local label;
• Moderate to severe plaque psoriasis patients eligible to use adalimumab according to the local label without any contraindication
• Patients have signed the authorization (or informed consent where applicable) to disclose and use personal health information after been prescribed with adalimumab.

Exclusion Criteria:

• Patients who are pregnant or breast feeding at enrolment or wish to become pregnant during the following adalimumab treatment and within 150 days since adalimumab discontinuation;
• Patients in any psoriasis related clinical trial at the time of enrolment, at baseline or at any point during the study follow-up;
• Patients with active tuberculosis or other severe infections (e.g. sepsis and opportunistic infections) as well as moderate to severe cardiac insufficiency.
• Patients with difficulties for adequately reading, understanding and completing patient questionnaires.

Adult patients with moderate to severe plaque psoriasis in China